UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number 001-37652
Biodexa Pharmaceuticals PLC
(Translation of registrant’s name into English)
1 Caspian Point,
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
Biodexa Pharmaceuticals plc (the “Company”) is furnishing this Report on Form 6-K to report on the appointment of PKF Littlejohn LLP as its independent registered public accounting firm, with an effective date of October 31, 2024, and the resignation of Forvis Mazars LLP (formerly known as Mazars LLP) as the Company’s independent registered public accounting firm with effect from October 25, 2024.
The change in auditors was made following notice from Forvis Mazars LLP of their intent to resign and a subsequent tender process. Both the commercial terms and expertise of the tender participants were assessed during the tender process. As a result of this process, the Audit Committee of the Board of Directors and the Board selected and, following the resignation of Forvis Mazars LLP, approved the appointment of PKF Littlejohn LLP as our independent registered public accounting firm. During the Company’s fiscal years ended December 31, 2022 and 2023, and through October 30, 2024, neither the Company, nor anyone acting on its behalf, consulted with PKF Littlejohn LLP regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided that PKF Littlejohn LLP concluded was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions) or a reportable event (as described in Item 16F(a)(1)(v) of Form 20-F).
The reports of Forvis Mazars LLP on our consolidated financial statements for the fiscal years ended December 31, 2022 and 2023 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle, except that the audit report for the years ended December 31, 2022 and 2023 contained a modification regarding the Company’s ability to continue as a going concern.
During the two fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through October 25, 2024, there were no disagreements, as that term is defined in Item 16F(a)(1)(iv) of Form 20-F, with Forvis Mazars LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Forvis Mazars LLP, would have caused Forvis Mazars LLP to make reference thereto in their reports on our consolidated financial statements for such fiscal years.
During the two fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through October 25, 2024, there were no “reportable events” as that term is defined in Item 16F(a)(1)(v) of Form 20-F.
The Company provided Forvis Mazars LLP with a copy of the disclosures it is making in this Report on Form 6-K and requested that Forvis Mazars LLP furnish it with a letter addressed to the U.S. Securities and Exchange Commission (“SEC”) stating whether or not it agrees with the above disclosures and, if not, stating the respects in which it does not agree. A copy of Forvis Mazars LLP’s letter to the SEC, dated November 1, 2024, is attached as Exhibit 16.1 to this Report on Form 6-K.
The Company intends to use this Report on Form 6-K and the accompanying exhibit to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending December 31, 2024, to the extent provided in and permitted by Paragraph 2 of the instructions to Item 16F of Form 20-F and plans to incorporate this Report on Form 6-K by reference into its Form 20-F to the extent necessary to satisfy such reporting obligations.
The information included in this Report on Form 6-K, including Exhibit 16.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of October 2024 is:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Biodexa Pharmaceuticals PLC |
| | | |
| Date: November 1, 2024 | By: | /s/ Stephen Stamp |
| | | Stephen Stamp |
| | | Chief Executive Officer and Chief Financial Officer |
